



Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Diabetes Care 2015;38:1181–1188 | DOI: 10.2337/dc14-2806

Arthur T. Sands,¹ Brian P. Zambrowicz,¹
Julio Rosenstock,² Pablo Lapuerta,¹
Bruce W. Bode,³ Satish K. Garg,⁴
John B. Buse,⁵ Phillip Banks,¹
Rubina Heptulla,⁶ Marc Rendell,⁷
William T. Cefalu,⁸ and Paul Strumph¹

OBJECTIVE

To assess the safety and efficacy of dual sodium–glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes.

RESEARCH DESIGN AND METHODS

We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or placebo in a randomized, double-blind trial assessing safety, insulin dose, glycemic control, and other metabolic parameters over 29 days of treatment.

RESULTS

In the sotagliflozin-treated group, the percent reduction from baseline in the primary end point of bolus insulin dose was 32.1% ($P = 0.007$), accompanied by lower mean daily glucose measured by continuous glucose monitoring (CGM) of 148.8 mg/dL (8.3 mmol/L) ($P = 0.010$) and a reduction of 0.55% (5.9 mmol/mol) ($P = 0.002$) in HbA_{1c} compared with the placebo group that showed 6.4% reduction in bolus insulin dose, a mean daily glucose of 170.3 mg/dL (9.5 mmol/L), and a decrease of 0.06% (0.65 mmol/mol) in HbA_{1c}. The percentage of time in target glucose range 70–180 mg/dL (3.9–10.0 mmol/L) increased from baseline with sotagliflozin compared with placebo, to 68.2% vs. 54.0% ($P = 0.003$), while the percentage of time in hyperglycemic range >180 mg/dL (10.0 mmol/L) decreased from baseline, to 25.0% vs. 40.2% ($P = 0.002$), for sotagliflozin and placebo, respectively. Body weight decreased (1.7 kg) with sotagliflozin compared with a 0.5 kg gain ($P = 0.005$) in the placebo group.

CONCLUSIONS

As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved glycemic control and the CGM profile with bolus insulin dose reduction, weight loss, and no increased hypoglycemia in type 1 diabetes.

Therapy for type 1 diabetes has advanced considerably since the historic publication of the Diabetes Control and Complications Trial (1) in 1993 with the introduction of new fast-acting and basal insulin analogs, more accurate blood glucose meters, smaller and more technically advanced insulin pumps, and the availability of continuous glucose monitoring (CGM). Despite these advances, sustained improvements in glycemic control are still associated with hypoglycemia and severe hypoglycemia (SH). The 12-month risk of SH associated with seizure or loss of consciousness was recently reported at 11.6% in adults and 9.9% in youth, rising

¹Lexicon Pharmaceuticals, Inc., The Woodlands, TX

²Dallas Diabetes and Endocrine Center, Dallas, TX

³Atlanta Diabetes Associates, Atlanta, GA

⁴University of Colorado Denver/Barbara Davis Center for Childhood Diabetes, Aurora, CO

⁵University of North Carolina School of Medicine, Chapel Hill, NC

⁶Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

⁷Creighton Diabetes Center, Omaha, NE

⁸Pennington Biomedical Research Center, Baton Rouge, LA

Corresponding authors: Arthur T. Sands, arthur.sands@bcm.edu, and Paul Strumph, pstrumph@lexpharma.com.

Received 26 November 2014 and accepted 12 March 2015.

Clinical trial reg. no. NCT01742208, clinicaltrials.gov.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-2806/-/DC1>.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

to 18.6% in adults with type 1 diabetes for >40 years (2,3). The cause of death for individuals with type 1 diabetes has been examined in several longitudinal studies, indicating that between 4 and 10% of deaths can be attributed to hypoglycemia (4–7), providing a stark reminder of the risks of tight glycemic control with insulin alone. Recent data also indicate that approximately one-third of patients are worried about hypoglycemia and a similar proportion purposely maintain a hyperglycemic state seeking a “safety margin” from hypoglycemia (8). Additionally, ~30% of patients with type 1 diabetes in the U.S. are obese (9,10) and ~50% of patients have metabolic syndrome (11). There is a clear need for the development of new adjunct therapies to insulin that can improve glycemic control in this population without weight gain or an increase in the risk of hypoglycemia.

Highly selective inhibitors of sodium–glucose cotransporter (SGLT) 2, the transporter primarily responsible for renal glucose reabsorption, are approved for the treatment of type 2 diabetes (12) and under exploration in patients with type 1 diabetes (13–15). SGLT1 is the primary transporter for absorption of glucose and galactose in the intestine (16). Sotagliflozin is a novel, orally delivered, small-molecule dual inhibitor of SGLT1 and SGLT2 that was designed to reduce glucose absorption in the gastrointestinal (GI) tract via SGLT1 inhibition and renal glucose reabsorption via SGLT2 inhibition (17). SglT1 knockout mice given a meal challenge containing glucose exhibit decreased blood glucose, increased delivery of glucose to the distal small intestine and cecum, and increased GLP-1 release indicating a potential utility for inhibition of intestinal SGLT1 (18,19). Homozygous knockout mice maintained on a diet containing glucose and galactose also exhibit unformed watery stools, decreased food intake, and reduced weight, findings consistent with glucose and galactose malabsorption, a condition characterized by severe diarrhea, in infants with mutations in SGLT1 (16). With this in mind, most pharmaceutical discovery programs focused on selective SGLT2 inhibitors to avoid potential GI side effects. However, heterozygous SglT1 knockout mice also exhibit increased delivery of glucose to the distal small intestine and cecum and increased GLP-1 release after a glucose-containing meal

challenge but have normal stools, normal food intake, and normal weight gain when maintained on a diet containing glucose and galactose (18). Additionally, it has been reported that most individuals in a large family cohort of patients with galactose malabsorption at birth could tolerate a normal diet by the age of 20 years, suggesting that severe reduction in SGLT1 activity is compatible with relatively normal GI function (20). These data were consistent with a “window” for achieving glycemic efficacy with potent SGLT2 inhibition and partial SGLT1 inhibition, thereby avoiding the GI side effects of complete SGLT1 inhibition. Sotagliflozin fulfilled these criteria with 20-fold selectivity for SGLT2 over SGLT1 with SGLT2 half-maximal inhibitory concentration of 0.0018 $\mu\text{mol/L}$ and SGLT1 half-maximal inhibitory concentration of 0.036 $\mu\text{mol/L}$ (17).

Inhibiting SGLT1, the major intestinal glucose transporter, holds promise to improve glucose control by reducing postprandial glucose peaks and stimulating release of GI peptides, such as GLP-1 and polypeptide tyrosine tyrosine (PYY) (18,19,21), that assist in glycemic and appetite control (22,23). Preclinical and clinical studies conducted to date have confirmed the effects of sotagliflozin on postprandial glucose, GLP-1, and PYY (17–19,24,25). In patients with type 2 diabetes, sotagliflozin treatment lowered HbA_{1c}, reduced body weight, and lowered blood pressure with a low risk of hypoglycemia (17,26). In a dose-ranging study in patients with type 2 diabetes inadequately controlled with metformin, HbA_{1c} reduction nearly doubled as sotagliflozin dose increased in the absence of additional increases in urinary glucose excretion (UGE) supporting meaningful intestinal SGLT1 inhibition (26). In a recent study in patients with type 2 diabetes and moderate to severe renal impairment (estimated glomerular filtration rate 15–59 mL/min/1.73 m²), sotagliflozin produced a significant decrease in PPG excursion and an increase in GLP-1 secretion (27). This difference was preserved in the patient subgroup with more severe renal impairment despite the expected reduction of UGE suggesting that, unlike the effects of SGLT2 inhibition, the effects of intestinal SGLT1 inhibition are maintained as kidney function declines.

We hypothesized that in type 1 diabetes, sotagliflozin would improve glycemic

control while concomitantly simplifying the insulin regimen without weight gain. In contrast to selective SGLT2 inhibitors, the additional inhibition of SGLT1 by sotagliflozin was predicted to lower postprandial glycemic excursions and decrease bolus insulin, thereby lowering the potential for postprandial hypoglycemia. Here, we present the results of a randomized, multicenter, placebo-controlled, double-blind evaluation of sotagliflozin treatment in adults with inadequately controlled type 1 diabetes as adjunct therapy to usual insulin delivery method: either continuous subcutaneous insulin infusion (CSII) or multiple dose injection (MDI).

RESEARCH DESIGN AND METHODS

Study Design

This study was a randomized, multicenter, placebo-controlled, double-blind evaluation of sotagliflozin in adult patients with type 1 diabetes using their previous insulin delivery regimen: either CSII or MDI. The study design is presented in Fig. 1.

The study was initiated with an open-label pioneer group ($n = 3$) on CSII to establish preliminary safety and to provide information on insulin dose adjustment during initiation of treatment. Subsequent to completion of treatment of the pioneer group, patients on either MDI or CSII were enrolled in the placebo-controlled portion of the study and randomly assigned 1:1, using an interactive web response system, to receive, in a double-blind fashion, either a total daily dose of 400 mg sotagliflozin or placebo taken within 15 min prior to breakfast for 29 days.

The initial 7 days (days –7 to –1) of the study were used to obtain baseline laboratory samples, to record baseline insulin doses through use of daily diaries, and to obtain at least 3 days of blinded CGM data on an outpatient basis during patients' usual insulin, dietary, and activity regimen. Days 1 and 2 of the study were conducted in an inpatient setting to allow supervision of initial insulin dose adjustments and to obtain multiple pharmacokinetic (PK) and pharmacodynamic (PD) samples. The first treatment dose (day 1) was administered before a mixed-meal tolerance test (MMTT) prior to breakfast with no bolus insulin administered. Basal insulin was continued unchanged. Subsequently, investigators adjusted the suggested dosage of short-acting insulin at each meal with guidance

Table 1—Demographic characteristics (intent-to-treat population)

Patient characteristics	Placebo (N = 17)	Sotagliflozin (N = 16)
Age (years), median (range)	34.0 (21, 57)	45.5 (21, 55)
Sex, n (%)		
Female	9 (53)	8 (50)
Male	8 (47)	8 (50)
Race, n (%)		
White/Caucasian	14 (82)	16 (100)
Asian	2 (12)	0
Other	1 (6)	0
Weight (kg), median (range)	72.7 (55.3, 104.6)	74.2 (55.6, 107.9)
BMI (kg/m ²), mean (SD)	26.2 (3.0)	27.1 (3.1)
Duration of diabetes (years), median (range)	18.5 (4.7, 40.8)	16.8 (3.4, 42.9)
HbA _{1c} (%), mean (SD)	7.98 (0.51)	7.94 (0.55)
HbA _{1c} (mmol/mol), mean (SD)	62.83 (5.66)	63.38 (6.04)
FPG (mmol/L), mean (SD)	8.89 (3.96)	9.45 (3.45)
Seated systolic BP (mmHg), mean (SD)	119.8 (7.0)	118.1 (9.2)
Serum sodium (mmol/L), mean (SD)	138.24 (3.75)	137.63 (2.45)
Serum creatinine (μmol/L), mean (SD)	76.11 (9.86)	76.94 (11.82)
Serum BUN (mmol/L), mean (SD)	4.68 (0.99)	4.96 (1.02)
Hematocrit, mean (SD)	41.94 (4.87)	41.63 (4.86)
Insulin therapy, n (%)		
MDI	5 (29)	6 (38)
CSII	12 (71)	10 (63)
Total daily insulin (IU/kg), mean	0.60	0.60
Daily insulin, ratio of bolus/total	0.45	0.49

BP, blood pressure.

Outcomes

Bolus Insulin

The percent change from baseline in total daily bolus insulin use was -32.0% in the sotagliflozin group and -6.4% in the placebo group ($P = 0.007$) (Tables 2 and 3). Given that sotagliflozin was administered once daily before breakfast, a prespecified subgroup analysis of bolus insulin use before major meals was conducted to detect differences throughout the day. Reductions of bolus insulin from baseline before each meal were noted in patients treated with sotagliflozin compared with placebo: -28.4% vs. 13.6% at breakfast ($P = 0.046$), -25.9% vs. 7.1% at lunch ($P = 0.08$), and -23.8% vs. 39.3% at dinner ($P = 0.052$) (Table 3). The effects of sotagliflozin on bolus insulin requirements were similar whether patients were on MDI or CSII.

Basal Insulin and Total Daily Insulin

The use of basal insulin was similar between the groups, and the change from baseline for both groups was minimal. There was a numerical decrease from baseline of 2.4% for the sotagliflozin group compared with a numerical increase from baseline of 0.2% in the placebo group ($P = 0.53$, Tables 2 and 3).

Total daily insulin was lower for the sotagliflozin group, with a reduction from baseline of 15.3% ($P = 0.002$) and a reduction of 0.7% for the placebo group ($P = 0.029$, difference between groups) (Tables 2 and 3).

Glucose Levels by CGM

Over the outpatient treatment period, sotagliflozin therapy resulted in a lower mean daily glucose as measured by CGM (Supplementary Fig. 1) of 148.8 mg/dL (8.3 mmol/L) compared with a placebo value of 170.3 mg/dL (9.5 mmol/L) ($P = 0.010$) (Table 3). In addition, patients in the sotagliflozin treatment group spent a greater percentage of time in the target glycemic range defined as ≥ 70 mg/dL (3.9 mmol/L) and ≤ 180 mg/dL (10.0 mmol/L) compared with placebo (68.2% vs. 54.0% , $P = 0.003$) (Table 3 and Supplementary Fig. 1), while percentage of time spent in the hyperglycemic range, >180 mg/dL (10.0 mmol/L), was lower compared with placebo (25.0% vs. 40.2% , $P = 0.002$) (Table 3 and Supplementary Fig. 1), as was percentage of time spent >250 mg/dL (13.9 mmol/L) (6.7% vs. 14.1% , $P < 0.008$) (Table 3). The sotagliflozin and placebo groups exhibited a

similar percentage of time spent in the hypoglycemic ranges of <70 mg/dL (3.9 mmol/L) (6.7% vs. 5.8% , $P = 0.80$) (Table 3 and Supplementary Fig. 1).

After meals, sotagliflozin treatment produced favorable effects on postprandial glycemic excursions as assessed by CGM during a 3-h period. In the sotagliflozin group, mean change from baseline at breakfast was -16.7 mg/dL (-0.93 mmol/L) vs. -4.2 mg/dL (-0.23 mmol/L) ($P = 0.034$) (Supplementary Table 2). The changes from baseline at lunch and dinner were numerically lower for sotagliflozin than placebo but did not reach statistical significance.

Notably, there was less glucose variability on sotagliflozin treatment as measured by MAGE, calculated as 120.8 mg/dL (6.7 mmol/L) for the sotagliflozin treatment group, compared with 145.5 mg/dL (8.1 mmol/L) for placebo ($P = 0.041$) (Table 3). CGM SD was also lower on sotagliflozin treatment, calculated as 50.0 for the sotagliflozin treatment group compared with 58.8 for placebo ($P = 0.022$) (Table 3). Consistent with the percentage of time spent in hyperglycemic ranges, the mean HBGI was reduced from baseline in the sotagliflozin group compared with an increase in the placebo group ($P = 0.006$) (Table 3).

HbA_{1c}

There was a significant decrease in HbA_{1c} of 0.55% (5.9 mmol/mol) from baseline after 29 days of treatment with sotagliflozin compared with 0.06% (0.65 mmol/mol) for the placebo group ($P = 0.002$) (Table 2). The effects of sotagliflozin on HbA_{1c} were similar whether patients were on MDI or CSII.

Hypoglycemia

Total hypoglycemic events defined as SMBG ≤ 70 mg/dL (3.9 mmol/L) in the placebo group numbered 354. Of these, 185 (52%) were symptomatic and 117 (33%) were asymptomatic. In the sotagliflozin treatment group, the total number of events was 304. Of these, 162 events (53%) were symptomatic and 80 events (26%) were asymptomatic. There were no SH events in either group. Hypoglycemic events per patient per day (PPD), defined as SMBG ≤ 70 mg/dL (3.9 mmol/L), declined significantly from baseline during treatment in both groups, and in both groups hypoglycemia PPD was 0.4 (Table 2). Hypoglycemic events PPD, by blinded CGM (defined as ≥ 10 continuous minutes of glucose readings <70 mg/dL

Table 2—Overall summary of results

	Placebo (N = 17)	Sotagliflozin (N = 16)	P
Efficacy			
HbA _{1c} change from baseline (%)	−0.06	−0.55*	0.002
FPG change from baseline assessed at day 29 (mg/dL)	39.0	−18.6	0.15
Daily bolus insulin change from baseline assessed at days 3–27 (%)	−6.4	−32.0*	0.007
Daily basal insulin change from baseline assessed at days 3–27 (%)	0.2	−2.4	0.53
Total daily insulin change from baseline assessed at days 3–27 (%)	−0.7	−15.3*	0.029
Mean body weight change from baseline assessed at day 29 (kg)	0.5	−1.7*	0.005
Postmeal urinary glucose (g/3 h) at day 29†	9.2	29.1	0.025
Postmeal plasma glucose AUC (mg · h/dL over 3 h) at day 29†	761	595	0.005
PYY postmeal AUC change from baseline assessed at day 29 (pmol/L · h over 3 h)	−0.7	6.0*	0.018
Seated systolic blood pressure change from baseline assessed at day 29 (mmHg)	−3.9	−4.9	0.45
Safety			
Patients with any TEAE (%)	12 (71)	14 (88)	N/A
Patients with SAE (both with DKA‡)	0	2	N/A
Hypoglycemic events (SMBG ≤70 mg/dL, baseline–day 36)	354	304	N/A
Documented symptomatic hypoglycemia (SMBG ≤70 mg/dL, baseline–day 36)	185	162	N/A
Asymptomatic hypoglycemia (SMBG ≤70 mg/dL, baseline–day 36)	117	80	N/A
SH	0	0	N/A
Hypoglycemia (SMBG ≤70 mg/dL, PPD) change from baseline at days 3–27	−0.4*	−0.7*	0.77
Hypoglycemia (CGM ≥10 continuous min <70 mg/dL, PPD) change from baseline assessed at days 3–27	−0.15	−0.09	0.75
Laboratory values associated with volume status			
Serum sodium (mmol/L), change from baseline at day 29 (day 36)	−1.00 (−0.53)	−0.50 (1.50)	N/A
Serum creatinine (μmol/L), change from baseline at day 29 (day 36)	−0.53 (1.53)	2.63 (0.63)	N/A
Serum BUN (mmol/L), change from baseline at day 29 (day 36)	0.41 (0.11)	1.02 (−0.41)	N/A
Hematocrit, change from baseline at day 29 (day 36)	−1.4 (0)	2.1 (1.5)	N/A

For laboratory values, change from baseline was assessed at day 29, the last day of therapy, and day 36, 1 week off therapy, unless otherwise specified. N/A, not applicable; SAE, serious adverse event. * $P < 0.05$, change from baseline. †Day 1 is not a true “baseline”; therefore, P values are calculated from two-sample t tests using the observed means. ‡Both were assessed as due to insulin pump and deemed not drug related. Bold values are statistically significant.

(3.9 mol/L), declined numerically during treatment in both groups.

Body Weight, PYY, Urinary Glucose, and Other Outcomes

Mean body weight decreased with sotagliflozin treatment compared with an increase in the placebo group (−1.7 kg vs. 0.5 kg) ($P = 0.005$) (Table 2). Change from baseline AUC after a meal challenge for PYY was increased by 6.0 pmol/L · h over 3 h in the sotagliflozin group and decreased by 0.7 pmol/L · h over 3 h with placebo ($P = 0.018$) (Table 2).

An MMTT performed on the last treatment day of the study showed a lower serum glucose 3-h AUC in the sotagliflozin group compared with placebo (595 mg · h/dL vs. 761 mg · h/dL, respectively, $P = 0.009$) (Table 2). The mean 3-h UGE was higher in the sotagliflozin group compared with placebo (29.1 g/3 h vs. 9.2 g/3 h, respectively, $P = 0.025$) (Table 2). Systolic blood pressure decreased in both groups, with a decline of 4.9 mmHg in the sotagliflozin-treated group and a decline of 3.9 with placebo ($P = 0.45$) (Table 2). Laboratory values associated with volume

status (serum sodium, serum creatinine, serum BUN [blood urea nitrogen], and hematocrit) were assessed at baseline, the last day of therapy (day 29), and 1 week after last dose of study medication (day 36). In the sotagliflozin group, there were numeric increases in most values, which returned toward baseline at day 36, consistent with reversible perfusion and volume effects. There were no meaningful changes in other exploratory end points including stimulated C-peptide, C-reactive protein, triglycerides, and uric acid (data not shown).

Adverse Events

Fourteen (88%) patients on sotagliflozin reported adverse events compared with 12 (71%) patients on placebo. No adverse events led to discontinuation from the study. The most frequently reported treatment-emergent adverse events (TEAEs) in the sotagliflozin group by MedDRA System Organ Class were GI disorders, eight sotagliflozin patients (50%) compared with three placebo patients (18%), with the most notable imbalance being three reports of nausea

on sotagliflozin versus one on placebo. Treatment differences in incidence of TEAEs were not statistically tested. TEAEs are summarized in Supplementary Table 1.

Two serious adverse events of diabetic ketoacidosis were reported in two patients using insulin infusion pumps and treated with sotagliflozin. Both cases of DKA were assessed by the investigators as pump related and were not related to the study drug. Details of the events are provided in Supplementary Table 1.

CONCLUSIONS

We evaluated dual inhibition of SGLT1 and SGLT2 using sotagliflozin as adjunct to insulin in inadequately controlled type 1 diabetes in a double-blind, placebo-controlled trial over 29 days. During the study period, patients continued their usual insulin delivery regimens while attempting to achieve American Diabetes Association–recommended glucose targets goals and maintaining their usual activity levels and diet. Treatment with 400 mg sotagliflozin given once daily before breakfast resulted in significant reductions in bolus insulin

Table 3—Summary of CGM and CGM-derived results and prespecified insulin dose analysis

	Placebo (N = 17)			Sotagliflozin (N = 16)			P
	Baseline	Treatment	Change from baseline value [%]	Baseline	Treatment	Change from baseline value [%]	
CGM mean daily glucose (mg/dL)	160.6 (25.9)	170.3 (24.0)	5.9 [NC]	163.6 (38.7)	148.8 (18.0)*	−14.0 [NC]	0.010
CGM hypoglycemia events/patient/day (≥10 continuous min <70 mg/dL)	1.09 (1.01)	0.90 (0.47)	−0.2 [NC]	1.06 (0.59)	0.95 (0.41)	−0.1 [NC]	0.75
CGM % time in ranges (mg/dL)							
<70	8.5 (9.5)	5.8 (4.7)	−2.3 [NC]	7.9 (7.3)	6.7 (5.0)	−1.5 [NC]	0.80
70–180	55.9 (12.1)	54.0 (12.0)	−0.2 [NC]	56.4 (15.6)	68.2 (12.1)*	11.6 [NC]	0.003
>180	35.6 (14.4)	40.2 (13.7)	2.5 [NC]	35.7 (18.3)	25.0 (11.2)*	−10.1 [NC]	0.002
>250	12.0 (9.3)	14.1 (7.9)	1.1 [NC]	15.3 (14.8)	6.7 (6.6)*	−7.9 [NC]	0.008
CGM variability measures							
SD (mg/dL)	57.2 (13.9)	58.8 (9.6)	1.2 [NC]	60.5 (16.5)	50.0 (12.2)*	−8.9 [NC]	0.022
Coefficient of variation	35.6 (8.8)	35.4 (5.2)	0.3 [NC]	37.4 (5.2)	33.7 (6.0)	−2.9 [NC]	0.41
MAGE	135.5 (34.9)	145.5 (25.6)	7.5 [NC]	145.5 (39.5)	120.8 (30.5)*	−20.0 [NC]	0.041
HBGI	8.7 (3.7)	9.7 (3.7)	0.5 [NC]	9.2 (6.5)	6.2 (3.1)*	−2.9 [NC]	0.006
LBGI	2.2 (2.2)	1.5 (1.1)*	−0.6 [NC]	1.9 (1.5)	1.8 (1.2)	−0.2 [NC]	0.61
Insulin dose data							
Total daily bolus (primary)	20.9 (14.0)	18.8 (11.2)	−2.1 [−6.4]	23.0 (11.6)	15.4 (9.2)	−7.3 [−32.0]	0.007
Total daily basal	26.1 (9.4)	25.9 (9.3)	−0.2 [0.2]	27.1 (7.1)	26.6 (8.7)	−0.5 [−2.4]	0.53
Total daily (basal + bolus)	45.9 (17.5)	44.4 (15.5)	−1.5 [−0.7]	47.0 (17.9)	37.6 (15.3)	−7.6 [−15.3]	0.029
Breakfast bolus	4.8 (4.1)	4.4 (2.9)	— [13.6]	5.6 (3.6)	3.4 (2.0)	— [−28.4]	0.046
Lunch bolus	5.6 (4.8)	5.0 (3.9)	— [7.1]	6.4 (3.9)	4.4 (2.7)	— [−25.9]	0.08
Dinner bolus	6.2 (5.7)	5.8 (4.2)	— [39.3]	7.2 (4.1)	5.3 (3.4)	— [−23.8]	0.052

Data are mean (SD) unless otherwise indicated. Arithmetic change from baseline is shown; P values are from least squares mean analyses of change from baseline scores (absolute and % change). The baseline analysis period consists of days −6 to −2, and the treatment analysis period consists of days 3–27. LBGI, low blood glucose index; NC, not calculated. *P < 0.05, change from baseline. Bold values are statistically significant.

dose while improving glycemic control by multiple measures including lower mean daily glucose, a higher percentage of time spent in target range, less time spent in hyperglycemic ranges, and lower HbA_{1c}.

Sotagliflozin also produced significant pre- and postmeal improvements in glucose levels by CGM. Improvement in postprandial glucose was also demonstrated by favorable effects during the MMTT, where compared with placebo, sotagliflozin produced a statistically significant decrease in 3-h plasma glucose AUC at the end of treatment. The primary effect of SGLT1 inhibition is reduction in postprandial glucose (19,29–31) and, of note, occurred with significantly lower bolus insulin used by patients on sotagliflozin. This contrasts with trials of empagliflozin and dapagliflozin, selective SGLT2 inhibitors, in type 1 diabetes that did not show any significant reductions in bolus insulin use (15,32,33). Further work is required to clarify the extent to which this discrepancy is driven by the SGLT1 inhibition of sotagliflozin versus differences in trial design. Importantly, the favorable effects on daily glycemic control and insulin use

were accompanied by a 0.55% reduction of HbA_{1c} after 29 days of treatment with sotagliflozin. In an 8-week open-label study in patients with type 1 diabetes, empagliflozin produced a 0.4% reduction in HbA_{1c} (32).

The reduction in bolus insulin use could contribute to a lower risk for postprandial hypoglycemia, and it is interesting to note that hypoglycemic events PPD were numerically lower than baseline for both treatment groups when measured by either SMBG or blinded CGM. Based on these findings, sotagliflozin provided clinically meaningful improvement in glycemic control without increased hypoglycemic events. Patients treated with sotagliflozin also demonstrated significant improvements in measures of glycemic variability based on 24-h CGM analysis during the treatment period. These measures included the 24-h SD, 24-h glucose interquartile range, HBGI (a predictor for hyperglycemia), mean daily sensor glucose, and MAGE.

Patients treated with sotagliflozin demonstrated weight loss (−1.7 kg) compared with a weight gain (0.5 kg) for the placebo group. The systolic

blood pressure decrease in the sotagliflozin group (−4.9 mmHg) was similar to the placebo group (−3.9 mmHg). Consistent with the SGLT1 inhibitory effects of sotagliflozin, postprandial GI hormone PYY was significantly increased and sotagliflozin's SGLT2 inhibitor effect was reflected by increased UGE. These parameters provide confirmation of sotagliflozin's dual mechanism of action of SGLT1 inhibition in the GI tract and SGLT2 inhibition in the kidney.

Four patients in the sotagliflozin group reported an AE of nausea compared with one patient in the placebo group, an effect possibly associated with increased GLP-1 activity. One case occurred 3 days after cessation of treatment. The three cases that occurred during treatment were early in onset, mild in intensity, and of short duration (2 days or less). No patient on sotagliflozin reported any genitourinary infections, while one patient on placebo reported cystitis in the posttreatment follow-up period. There were no cases of SH reported, and numerically less hypoglycemic events PPD in the sotagliflozin-treated group compared with placebo. Two patients in the sotagliflozin group reported an event

of DKA, which was attributed (by the investigators) to insulin pump therapy. Both cases were associated with high laboratory blood glucose readings (>350 mg/dL [19.4 mmol/L]) at presentation, a finding expected in DKA. Nonetheless, given the serious nature of such events, DKA will be closely monitored in all future type 1 diabetes trials. Notably, two cases of DKA were reported in patients with type 1 diabetes receiving the selective SGLT2 inhibitor empagliflozin, but in both cases the patients presented with blood glucose levels lower than typically associated with DKA (14,32).

This initial study of sotagliflozin in type 1 diabetes had several limitations. With the known effects of sotagliflozin on reducing glucose absorption, bolus insulin administration was closely monitored in an inpatient setting during the first 48 h of the study, and guidance for insulin dosing upon first dosing with sotagliflozin was conservative with an emphasis on patient safety in an effort to lower the theoretical risk for episodes of SH. This could have introduced bias in the results favoring a reduction of bolus insulin use compared with basal over the outpatient treatment period. Finally, highly significant reductions in insulin doses achieved in some patients may have led certain participants or caregivers to believe they were effectively unblinded during the study, introducing behavioral biases that could have impacted the results given the small numbers of patients enrolled in this study.

Although insulin provides a lifesaving therapy for individuals with type 1 diabetes, the challenges and burden of managing the disease with insulin therapy alone remain daunting. As work continues to develop disease-modifying treatments such as the artificial pancreas, β -cell transplantation, and immunomodulatory therapy to protect β -cells, efforts must also be made to identify adjunct therapies that could be used in combination with insulin to improve glycemic control, lower the burden of disease, and improve quality of life. After 29 days' treatment, sotagliflozin, a next-generation dual SGLT1 and SGLT2 inhibitor, significantly reduced HbA_{1c} levels, daily bolus and total daily insulin dose, postprandial blood glucose, and body weight, with no increase in hypoglycemia risk. In addition, sotagliflozin significantly improved time spent in the glucose range as measured

by the following CGM glucose indices: mean daily glucose; percent time spent between 70 and 180 mg/dL, >180 mg/dL, and >250 mg/dL; and glucose variability (mean SD, MAGE, and HBGI). Sotagliflozin as an adjunctive treatment to insulin improved both glucose control and glycemic variability. Larger studies of a longer duration are needed to confirm these findings.

Acknowledgments. The authors thank Ike Ogbaa for protocol development and medical monitoring, Sangeeta Sawhney for data review and analysis, Paul Tubbs for project management, Ernest Wang for study management, and Kristi Boehm for assistance with manuscript writing, editing, and QC. All parties providing assistance currently are employees of Lexicon Pharmaceuticals, Inc., or were employees at the time the study was conducted (I.O.).

Funding. The Robert and Janice McNair Foundation, Houston, TX, partly funded this study. R.H. has received grant support from the NIH. B.W.B. has received research and grant support from the Jaeb Center for Health Research. S.K.G. has received speaking/advisory board consulting fees from the National Institute of Diabetes and Digestive and Kidney Diseases and JDRF and has received research grants from the National Institute of Diabetes and Digestive and Kidney Diseases, JDRF, and T1D Exchange.

Duality of Interest. Lexicon Pharmaceuticals, Inc., also funded the study. A.T.S. and B.P.Z. were employees of Lexicon Pharmaceuticals, Inc., at the time the study was conducted and own stock. P.L., P.B., and P.S. are employees of Lexicon Pharmaceuticals, Inc., and own stock. J.R. has had grants/research support, served on scientific advisory boards for, and received honorarium or consulting fees from manufacturers of SGLT2 inhibitors Janssen, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Pfizer, and Lexicon. B.W.B. is employed by Atlanta Diabetes Associates and is a partner with Atlanta Diabetes Associates, and his employer has received research and grant support from Lexicon Pharmaceuticals, Inc. S.K.G. has received speaking/advisory board consulting fees from Eisai, Johnson & Johnson, Medtronic, Novo Nordisk, Lexicon, Roche, and Sanofi and has received research grants from Eli Lilly, Halozyme, Novo Nordisk, Merck, MannKind, Lexicon, Medtronic, T1D Exchange, and Sanofi. J.B.B. is an investigator and/or consultant, without any direct financial benefit, under contracts between his employer and Andromeda; Astellas; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Dance Pharmaceuticals; Elcelyx; Eli Lilly; GI Dynamics; GlaxoSmithKline; Halozyme; Hoffmann-La Roche; Intarcia Therapeutics; Johnson & Johnson; Lexicon Pharmaceuticals, Inc.; LipoScience; Medtronic; Merck; Metabolic Solutions Development Company; Metabolon; Metavention; Novartis; Novo Nordisk; Orexigen; Osiris; Pfizer; Rhythm; Sanofi; Takeda; Tolerex; Transtech Pharma; Veritas; and Verva and is a consultant to PhaseBio Pharmaceuticals, Inc., for which work he has personally received stock options and payments. R.H. is a consultant for MannKind and Lexicon Pharmaceuticals, Inc.; has received

grant support from Lexicon Pharmaceuticals, Inc.; does contract research with Medtronic; and has an investment interest in Theralin Diabetes. W.T.C. has served as principal investigator on both basic research and clinical research grants awarded to his institutions from AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Sanofi, and Lexicon Pharmaceuticals, Inc., and has served as a consultant for Intarcia Therapeutics and Sanofi. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. A.T.S. wrote the manuscript. B.P.Z. contributed to the manuscript and reviewed and edited the manuscript. J.R. contributed to the manuscript and reviewed and edited the manuscript. P.L. contributed to the manuscript and reviewed and edited the manuscript. B.W.B. contributed to the manuscript and reviewed and edited the manuscript. S.K.G. contributed to the manuscript and reviewed and edited the manuscript. J.B.B. contributed to the manuscript and reviewed and edited the manuscript. P.B. analyzed the data, contributed to the manuscript, and reviewed and edited the manuscript. R.H. contributed to the manuscript and reviewed and edited the manuscript. M.R. contributed to the manuscript and reviewed and edited the manuscript. W.T.C. contributed to the manuscript and reviewed and edited the manuscript. P.S. contributed to the manuscript and reviewed and edited the manuscript. A.T.S. and P.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. **Prior Presentation.** This study was presented at the 75th Scientific Sessions of the American Diabetes Association, Boston, MA, 5–9 June 2015.

References

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–986
2. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. *J Clin Endocrinol Metab* 2013;98:3411–3419
3. Cengiz E, Xing D, Wong JC, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. *Pediatr Diabetes* 2013;14:447–454
4. Patterson CC, Dahlquist G, Harjutsalo V, et al. Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. *Diabetologia* 2007;50:2439–2442
5. Jacobson AM, Musen G, Ryan CM, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. *N Engl J Med* 2007;356:1842–1852
6. Feltbower RG, Bodansky HJ, Patterson CC, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. *Diabetes Care* 2008;31:922–926

7. Skrivarhaug T, Bangstad H-J, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. *Diabetologia* 2006;49:298–305
8. Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. *Expert Rev Pharmacoecon Outcomes Res* 2013;13:123–130
9. Larkin ME, Backlund J-Y, Cleary P, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. *Diabet Med* 2010;27:451–458
10. Łuczynski W, Szypowska A, Głowińska-Olszewska B, Bossowski A. Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy. *Eur J Pediatr* 2011;170:891–898
11. Wajchenberg BL, Feitosa AC, Rassi N, Lerário AC, Betti RTB. Glycemia and cardiovascular disease in type 1 diabetes mellitus. *Endocr Pract* 2008;14:912–923
12. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. *Diabetes Metab Syndr Obes* 2013;6:453–467
13. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β -cell function. *Diabetes Care* 2011;34:1463–1468
14. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation* 2014;129:587–597
15. Henry RR, Rosenstock RR, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. *Diabetes Care* 2015;38:412–419
16. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. *Physiol Rev* 2011;91:733–794
17. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. *Clin Pharmacol Ther* 2012;92:158–169
18. Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking SglT1 and SglT2. *Am J Physiol Endocrinol Metab* 2013;304:E117–E130
19. Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. *J Pharmacol Exp Ther* 2013;345:250–259
20. Xin B, Wang H. Multiple sequence variations in SLC5A1 gene are associated with glucose-galactose malabsorption in a large cohort of Old Order Amish. *Clin Genet* 2011;79:86–91
21. Shibasaki T, Tomae M, Ishikawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. *J Pharmacol Exp Ther* 2012;342:288–296
22. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology* 2007;132:2131–2157
23. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. *Nature* 2002;418:650–654
24. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. *Clin Ther* 2013;35:273–285.e7
25. Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. *Clin Ther* 2013;35:1162–1173.e8
26. Rosenstock J, Cefalu W, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. *Diabetes Care* 2015;38:431–438
27. Zambrowicz B, Lapuerta P, Strumph P, et al. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. *Clin Ther* 2015;37:71–82, e12
28. Baghurst PA. Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. *Diabetes Technol Ther* 2011;13:296–302
29. Centers for Disease Control and Prevention. *National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States*. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
30. Sakuma S, Teraoka Y, Sagawa T, et al. Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transporter-mediated D-glucose uptake. *Eur J Pharm Biopharm* 2010;75:366–374
31. Dobbins RL, Chen L, Liu YJ, et al. Glucose transport via SGLT1 is critical for post-prandial GIP secretion in rats and humans (Abstract). *Diabetes* 2012;61(Suppl. 1):A475–A476
32. Perkins BA, Cherney DZI, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. *Diabetes Care* 2014;37:1480–1483
33. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. *Endocr Pract* 2013;19:963–967